hydroxyurea has been researched along with Bleeding in 53 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 9.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| "Hydroxyurea is effective in preventing thrombosis in high-risk patients with essential thrombocythemia." | 9.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| "Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera." | 9.01 | Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. ( Barbui, T; Carobbio, A; De Stefano, V; Ferrari, A; Finazzi, G; Ghirardi, A; Masciulli, A; Vannucchi, AM, 2019) |
| "Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease." | 8.83 | Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006) |
| "Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown." | 8.12 | Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022) |
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 5.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| " As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0." | 5.11 | Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005) |
| "Hydroxyurea is effective in preventing thrombosis in high-risk patients with essential thrombocythemia." | 5.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| "Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera." | 5.01 | Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. ( Barbui, T; Carobbio, A; De Stefano, V; Ferrari, A; Finazzi, G; Ghirardi, A; Masciulli, A; Vannucchi, AM, 2019) |
| " The aim of this study was to meta-analyze currently available data comparing anagrelide to hydroxyurea for reduction of rates of thrombosis, bleeding and death among patients with ET." | 4.91 | Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. ( Chai-Adisaksopha, C; Garcia, D; Samuelson, B, 2015) |
| "Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease." | 4.83 | Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006) |
| " Results of the first phase III trial (PT1) that compared anagrelide/aspirin with hydroxyurea/aspirin have sparked an intense discussion, given that the combination of anagrelide and aspirin causes more bleeding complications in the gastrointestinal tract." | 4.83 | Anagrelide: what was new in 2004 and 2005? ( Petrides, PE, 2006) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown." | 4.12 | Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022) |
| "Maximal fetal hemoglobin (Hb F) elevations in the baboon subsequent to phenyl hydrazine-induced hemolytic anemia, bleeding, bleeding plus hydroxyurea (HU), or cytosine arabinoside were two to three times lower than those achieved with bleeding plus 5-azacytidine (azaC)." | 3.67 | On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation. ( DeSimone, J; Hall, L; Heller, P; Lavelle, D; Zwiers, D, 1986) |
| "A 34% response was obtained in 202 evaluable patients in the terminal phase of chronic granulocytic leukemia using combinations of hydroxyurea, 6-mercaptopurine, and corticosteroids." | 3.66 | Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. ( Cavalli, F; Coleman, M; Glidewell, O; Holland, JF; Kostinas, JE; Pajak, TF; Rai, KR; Silver, RT, 1980) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Major bleeding is rare and seems to be related to higher platelet counts." | 2.42 | Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. ( Barbui, T; Finazzi, G, 2003) |
| "Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen." | 2.41 | [What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000) |
| "Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| "Major bleeding is rare and seem to be related to higher platelet counts: therefore, a platelet count over 1500 x 10(9)/L is generally regarded as an indication for cytoreduction." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| "Hydroxyurea treatment was initiated, leading to a gradual decrease in platelet count." | 1.62 | Differential diagnostic and treatment difficulties in a patient with acquired von Willebrand syndrome. ( Bedekovics, J; Bereczky, Z; Illés, Á; Kracskó, B; Magyari, F; Schlammadinger, Á, 2021) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Hydroxyurea was the most commonly used cytoreductive therapy." | 1.46 | Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Bilgir, O; Çağlıyan, G; Çekdemir, D; Cömert, M; Haznedaroğlu, İC; İlhan, O; Kaya, E; Özdemirkıran, F; Şahin, F; Saydam, G; Soyer, N; Ünal, A; Vural, F; Yılmaz, M, 2017) |
| "Hydroxyurea treatment was not related to leukemic transformation." | 1.43 | Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Akay, OM; Andıç, N; Bolaman, AZ; Kadıköylü, VG; Ünübol, M; Yağcı, E; Yavaşoğlu, İ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.43) | 18.7374 |
| 1990's | 10 (18.87) | 18.2507 |
| 2000's | 17 (32.08) | 29.6817 |
| 2010's | 17 (32.08) | 24.3611 |
| 2020's | 4 (7.55) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Larrán, A | 3 |
| Garrote, M | 1 |
| Ferrer-Marín, F | 2 |
| Pérez-Encinas, M | 1 |
| Mata-Vazquez, MI | 1 |
| Bellosillo, B | 2 |
| Arellano-Rodrigo, E | 1 |
| Gómez, M | 2 |
| García, R | 1 |
| García-Gutiérrez, V | 1 |
| Gasior, M | 1 |
| Cuevas, B | 1 |
| Angona, A | 2 |
| Gómez-Casares, MT | 2 |
| Martínez, CM | 1 |
| Magro, E | 1 |
| Ayala, R | 1 |
| Del Orbe-Barreto, R | 1 |
| Pérez-López, R | 1 |
| Fox, ML | 1 |
| Raya, JM | 1 |
| Guerrero, L | 1 |
| García-Hernández, C | 1 |
| Caballero, G | 1 |
| Murillo, I | 1 |
| Xicoy, B | 2 |
| Ramírez, MJ | 1 |
| Carreño-Tarragona, G | 1 |
| Hernández-Boluda, JC | 2 |
| Pereira, A | 1 |
| Nicol, C | 1 |
| Ajzenberg, N | 1 |
| Lacut, K | 1 |
| Couturaud, F | 1 |
| Lippert, E | 1 |
| Pan-Petesch, B | 1 |
| Ianotto, JC | 1 |
| Cilia, K | 1 |
| Borg, J | 1 |
| Bugeja, M | 1 |
| Farrugia, E | 1 |
| Magyari, F | 1 |
| Kracskó, B | 1 |
| Bedekovics, J | 1 |
| Bereczky, Z | 1 |
| Illés, Á | 1 |
| Schlammadinger, Á | 1 |
| Harrison, CN | 3 |
| Mead, AJ | 1 |
| Panchal, A | 1 |
| Fox, S | 1 |
| Yap, C | 1 |
| Gbandi, E | 1 |
| Houlton, A | 1 |
| Alimam, S | 1 |
| Ewing, J | 1 |
| Wood, M | 1 |
| Chen, F | 1 |
| Coppell, J | 1 |
| Panoskaltsis, N | 1 |
| Knapper, S | 1 |
| Ali, S | 1 |
| Hamblin, A | 1 |
| Scherber, R | 1 |
| Dueck, AC | 1 |
| Cross, NCP | 1 |
| Mesa, R | 1 |
| McMullin, MF | 1 |
| Tefferi, A | 5 |
| Barbui, T | 10 |
| Al-Sawaf, O | 1 |
| Köhler, P | 1 |
| Eichenauer, DA | 1 |
| Böll, B | 1 |
| Kochanek, M | 1 |
| Shimabukuro-Vornhagen, A | 1 |
| Ferrari, A | 1 |
| Carobbio, A | 1 |
| Masciulli, A | 1 |
| Ghirardi, A | 1 |
| Finazzi, G | 8 |
| De Stefano, V | 1 |
| Vannucchi, AM | 2 |
| Cervantes, F | 2 |
| Besses, C | 2 |
| Fu, R | 1 |
| Zhang, L | 1 |
| Yang, R | 1 |
| Singh, A | 1 |
| Chaudhary, R | 1 |
| Nityanand, S | 1 |
| Martínez-Avilés, L | 1 |
| Antelo, ML | 1 |
| Burgaleta, C | 1 |
| Mata, MI | 1 |
| Martínez-Trillos, A | 1 |
| Durán, MA | 1 |
| Marcote, B | 1 |
| Ancochea, A | 1 |
| Senín, A | 1 |
| Vicente, V | 1 |
| Kreher, S | 1 |
| Ochsenreither, S | 1 |
| Trappe, RU | 1 |
| Pabinger, I | 1 |
| Bergmann, F | 1 |
| Petrides, PE | 2 |
| Koschmieder, S | 1 |
| Matzdorff, A | 1 |
| Tiede, A | 1 |
| Griesshammer, M | 2 |
| Riess, H | 1 |
| Lim, Y | 1 |
| Lee, JO | 1 |
| Kim, SH | 1 |
| Kim, JW | 1 |
| Kim, YJ | 1 |
| Lee, KW | 1 |
| Lee, JS | 1 |
| Bang, SM | 1 |
| Samuelson, B | 1 |
| Chai-Adisaksopha, C | 1 |
| Garcia, D | 1 |
| Soyer, N | 1 |
| Haznedaroğlu, İC | 1 |
| Cömert, M | 1 |
| Çekdemir, D | 1 |
| Yılmaz, M | 1 |
| Ünal, A | 1 |
| Çağlıyan, G | 1 |
| Bilgir, O | 1 |
| İlhan, O | 1 |
| Özdemirkıran, F | 1 |
| Kaya, E | 1 |
| Şahin, F | 1 |
| Vural, F | 1 |
| Saydam, G | 1 |
| Andıç, N | 1 |
| Ünübol, M | 1 |
| Yağcı, E | 1 |
| Akay, OM | 1 |
| Yavaşoğlu, İ | 1 |
| Kadıköylü, VG | 1 |
| Bolaman, AZ | 1 |
| Campbell, PJ | 2 |
| Bareford, D | 2 |
| Erber, WN | 1 |
| Wilkins, BS | 2 |
| Wright, P | 1 |
| Buck, G | 2 |
| Wheatley, K | 2 |
| Green, AR | 3 |
| Rolf, N | 1 |
| Suttorp, M | 1 |
| Budde, U | 1 |
| Siegert, G | 1 |
| Knoefler, R | 1 |
| Dingli, D | 1 |
| Chernoff, N | 1 |
| Rogers, JM | 1 |
| Sonmez, M | 1 |
| Saglam, F | 1 |
| Karahan, SC | 1 |
| Erkut, N | 1 |
| Mentese, A | 1 |
| Sonmez, B | 1 |
| Ucar, F | 1 |
| Topbas, M | 1 |
| Ovali, E | 1 |
| Ruggeri, M | 2 |
| Rodeghiero, F | 3 |
| Cazzola, M | 1 |
| Barosi, G | 1 |
| Grossi, A | 2 |
| Gugliotta, L | 1 |
| Liberato, LN | 1 |
| Marchetti, M | 1 |
| Mazzucconi, MG | 1 |
| Tura, S | 1 |
| Elliott, MA | 1 |
| East, CL | 1 |
| van der Walt, JD | 1 |
| Reilly, JT | 1 |
| Grigg, AP | 1 |
| Revell, P | 1 |
| Woodcock, BE | 1 |
| Costello, R | 1 |
| O'Callaghan, T | 1 |
| Sébahoun, G | 1 |
| Gisslinger, H | 1 |
| Cacciola, RR | 1 |
| Di Francesco, E | 1 |
| Pezzella, F | 1 |
| Tibullo, D | 1 |
| Giustolisi, R | 1 |
| Cacciola, E | 1 |
| Coleman, M | 1 |
| Silver, RT | 1 |
| Pajak, TF | 1 |
| Cavalli, F | 1 |
| Rai, KR | 1 |
| Kostinas, JE | 1 |
| Glidewell, O | 1 |
| Holland, JF | 1 |
| Millicovsky, G | 1 |
| DeSesso, JM | 1 |
| Cortelazzo, S | 1 |
| Vestri, O | 1 |
| Galli, M | 1 |
| van Genderen, PJ | 3 |
| Michiels, JJ | 3 |
| van der Poel-van de Luytgaarde, SC | 1 |
| van Vliet, HH | 1 |
| Heimpel, H | 1 |
| Pearson, TC | 1 |
| Dupuy, E | 1 |
| Kiladjian, JJ | 1 |
| Brière, J | 1 |
| Leenknegt, H | 1 |
| Silverstein, MN | 2 |
| Randi, ML | 2 |
| Rossi, C | 2 |
| Fabris, F | 2 |
| Menapace, L | 1 |
| Girolami, A | 2 |
| Solberg, LA | 1 |
| Hachulla, E | 1 |
| Rose, C | 1 |
| Trillot, N | 1 |
| Caulier-Leleu, MT | 1 |
| Pasturel-Michon, U | 1 |
| Steinheider, G | 1 |
| Seidel, HJ | 1 |
| Kreja, L | 1 |
| Longo, G | 1 |
| Rafanelli, D | 1 |
| Rossi Ferrini, P | 1 |
| Lavelle, D | 1 |
| DeSimone, J | 1 |
| Heller, P | 1 |
| Zwiers, D | 1 |
| Hall, L | 1 |
| Gunz, FW | 1 |
| Levi, JA | 1 |
| Vincent, PC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for hydroxyurea and Bleeding
| Article | Year |
|---|---|
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.
Topics: Hemorrhage; Humans; Hydroxyurea; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Risk Factors; | 2019 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; | 2013 |
Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Topics: Hemorrhage; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombosis | 2015 |
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
Topics: Aged; Agranulocytosis; Alkylating Agents; Clinical Trials as Topic; Combined Modality Therapy; Disea | 2006 |
Hypoxia and the Edema Syndrome: elucidation of a mechanism of teratogenesis.
Topics: Abnormalities, Drug-Induced; Animals; Blister; Chick Embryo; Cocaine; Edema; Epinephrine; Hematoma; | 2010 |
Special issues in myeloproliferative neoplasms.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Child; Female; Hemorrhage; Humans; Hydroxyur | 2011 |
Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
Topics: Alkylating Agents; Hemorrhage; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Count; | 2003 |
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria | 2004 |
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Topics: Aged; Aspirin; Hemorrhage; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Risk Factors; Thromb | 2005 |
[Treatment of essential thrombocythemia].
Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; | 2005 |
Anagrelide: what was new in 2004 and 2005?
Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, | 2006 |
Update on diagnosis and management of essential thrombocythemia.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhag | 2006 |
Primary thrombocythemia: diagnosis, clinical manifestations and management.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Diagnosis, Differential; Female; Hemorrhage; Humans; Hydro | 1993 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He | 1999 |
A clinical update in polycythemia vera and essential thrombocythemia.
Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal | 2000 |
[What vascular events suggest a myeloproliferative disorder?].
Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi | 2000 |
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol | 2001 |
[Essential thrombocythemia: conventional therapy].
Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo | 1991 |
7 trials available for hydroxyurea and Bleeding
| Article | Year |
|---|---|
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance; Female; Hemorrhage; Humans; Hy | 2017 |
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres | 2014 |
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Agg | 2009 |
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F | 2005 |
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degrada | 2007 |
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; | 1995 |
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr | 1999 |
24 other studies available for hydroxyurea and Bleeding
| Article | Year |
|---|---|
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Topics: Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Nitriles; Poly | 2022 |
Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors-Learnings from a Large Cohort.
Topics: Aspirin; Hemorrhage; Humans; Hydroxyurea; Male; Polycythemia Vera; Risk Factors; Thrombocythemia, Es | 2022 |
Bilateral adrenal and pulmonary haemorrhages as an initial presentation of polycythaemia vera.
Topics: Bone Marrow; Hemorrhage; Humans; Hydrocortisone; Hydroxyurea; Hyperplasia; Male; Polycythemia Vera | 2022 |
Differential diagnostic and treatment difficulties in a patient with acquired von Willebrand syndrome.
Topics: Aged, 80 and over; Blood Transfusion; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Male; Thro | 2021 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Anticoagulants; Combined Modality Therapy; Dobutamine; Ex | 2019 |
Successful management of acute bleeding in essential thrombocythemia using automated cell separator.
Topics: Administration, Oral; Adolescent; Automation; Blood Platelets; Body Weight; Cell Separation; Female; | 2014 |
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo
Topics: Anticoagulants; Disease Susceptibility; Drug Interactions; Female; Hemorrhage; Heparin, Low-Molecula | 2014 |
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual; | 2015 |
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Chronic Disease; Fe | 2017 |
Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Hemorrhage; Humans; Hydroxyurea | 2016 |
Essential thrombocythaemia in a teenage girl resulting in acquired von Willebrand syndrome with joint haemorrhage and menorrhagia.
Topics: Adolescent; Antigens, CD34; Blood Cell Count; Blood Platelets; Female; Hemorrhage; Humans; Hydroxyur | 2010 |
Treatment related changes in antifibrinolytic activity in patients with polycythemia vera.
Topics: Adult; Aged; alpha-2-Antiplasmin; Biomarkers; Carboxypeptidase B2; Case-Control Studies; Female; Fib | 2010 |
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incid | 2003 |
Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.
Topics: Adult; Cohort Studies; Disease Progression; Evidence-Based Medicine; Expert Testimony; Female; Hemor | 2004 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia | 2005 |
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies.
Topics: Daunorubicin; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Human | 1980 |
Cardiovascular alterations in rabbit embryos in situ after a teratogenic dose of hydroxyurea: an in vivo microscopic study.
Topics: Animals; Cardiac Tamponade; Cardiovascular System; Cerebral Hemorrhage; Embryo, Mammalian; Female; H | 1980 |
Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.
Topics: Adult; Bleeding Time; Female; Hemorrhage; Humans; Hydroxyurea; Mucous Membrane; Platelet Count; Skin | 1994 |
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha | 1997 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Characterization of a Friend virus-replicating target cell.
Topics: Animals; Blood Transfusion; Bone Marrow Cells; Cell Transformation, Viral; Colony-Forming Units Assa | 1979 |
On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation.
Topics: Anemia, Hemolytic; Animals; Azacitidine; Cytarabine; DNA; Erythropoiesis; Fetal Hemoglobin; Hemorrha | 1986 |
The outlook for the adult with acute leukaemia, 1972.
Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Cytarabine; Drug Combinations; Female; | 1972 |